VitalConnect®, Inc., a leader in remote and in-hospital wearable biosensor technology, today announced closing on an oversubscribed Series F financing in excess of $30 million.  The financing round was led by Revelation Partners with significant participation from the company’s existing investors, including Pacific General Ventures and EW Healthcare Partners. 

Revelation Partners announced today that it is expanding its team with the addition of Rob Rein as Vice President at the firm. The firm, which has over $1.5 billion of capital under management, provides liquidity and flexible capital solutions to companies, investors, and general partners across all healthcare sub sectors.

Carrum Health today announced an oversubscribed $45 million Series B financing led by OMERS Growth Equity. Revelation Partners joined the round along with return investors Tiger Global, Wildcat Venture Partners, Cross Creek and SpringRock Ventures. Carrum Health will use the funding to expand its growing oncology benefit offerings and scale its surgical care service lines to give employees access to the top 10% of doctors and providers across the country while helping employers control healthcare spendin

Vedanta Biosciences, a clinical-stage company that is developing a potential new category of oral therapies based on defined bacterial consortia, today announced that it has raised $106.5 million to support pivotal-stage development of its lead candidate, VE303, for the prevention of recurrent Clostridioides difficile  infection (CDI), and a Phase 2 study of VE202 for ulcerative colitis, among other development activities.

Arcadia (Arcadia.io), a leading data analytics platform for healthcare, today announced $125 million in financing from Vista Credit Partners, the credit-lending arm of Vista Equity Partners and a strategic investor and financing partner focused on the enterprise software, data and technology market. 

Metabolon, Inc., the global leader in providing metabolomics solutions that advance a wide variety of research, diagnostic, therapeutic development, and precision medicine applications, today announced that it has closed on $25 million of additional equity funding. The proceeds will be used for general corporate purposes, helping Metabolon further accelerate commercialization activities and continue advancing its well-defined R&D roadmap.